Worth reading
69In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
17
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ending March 202710 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥30,002 million+17.0%
Operating profit¥3,980 million+27.3%
Ordinary income¥4,142 million+26.3%
Net income¥2,853 million+25.2%
Selling, general and administrative expenses¥5,288 million
Gross Profit Margin
Rate30.9%
Year on year against the same period last year+0.2Pt
Operating profit margin
Rate13.3%
Year on year against the same period last year+1.1Pt
Results for the three months of the current quarterRevenue: ¥30,002 million; gross profit: ¥9,269 million; operating profit: ¥3,980 million; ordinary profit: ¥4,142 million; profit attributable to owners of parent for the quarter: ¥2,853 million
Full-year earnings forecast
Net Sales
¥117,850 million
Gross profit
¥35,680 million
Operating profit
¥12,900 million
Ordinary income
¥13,350 million
Profit attributable to owners of the parent
¥8,970 million
Annual dividend
66 Yen per share
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Q1 significantly exceeded expectationsBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Gross profit
Impact of higher sales+¥1.34 billion
Gross margin improvement+¥40 million
Product mix+¥60 million
Price revision+¥80 million
Foreign Exchange-¥100 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Laboratory and Industry segment revenue growth rateUp 7.5% year on year
Medical segment revenue growth rate1.0% increase
Full-year gross marginExpected to remain at the previous year's level (30.3%)
Extraordinary loss¥244 million expected
New initiatives
- Launch of the new AXEL 2.0 search engine
- Establishment and planned completion of a new Rental & Calibration Center
- Expansion of Smart DC
- Updating delivery information and securing alternative products through system integration with suppliers
Key KPIsA metric the company considers important as a management benchmark.
- Total e-commerce sales¥11,173 millionYear on year against the same period last year+28.2%
- Product Range1,408 10,000 productsYear on year against the same period last year+10.9%
- Sales of products listed exclusively online¥6,548 millionYear on year against the same period last year+33.5%
- Service revenue¥943 millionYear on year against the same period last year+2.5%
- Original-product sales¥10,220 millionYear on year against the same period last year+22.6%
- Overseas Revenue¥1,674 millionYear on year against the same period last year+10.1%
Segment results
Laboratory
Net Sales¥18,610 million
Year on year against the same period last year+17.3%
Industry
Net Sales¥6,696 million
Year on year against the same period last year+18.5%
Medical
Net Sales¥4,543 million
Year on year against the same period last year+14.2%
Risk amount incorporated into the outlookThe amount representing the range of variation the company expects in its forecast.
Extraordinary loss of ¥244 million (demolition of the old Rental & Calibration Center building and consolidation of logistics bases in the Kanto area)Number of employees
Headcount increased by 47 from the end of Q1 of the previous fiscal yearCapital expenditures
¥219 million increase in property, plant and equipment from the end of the previous fiscal year
Annual Dividend
Annual dividend per shareAnnual dividend per share: ¥66.00
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥30,002 million (YoY +17.0%) |
| Operating profit | ¥3,980 million (YoY +27.3%) |
| Ordinary income | ¥4,142 million (YoY +26.3%) |
| Net income | ¥2,853 million (YoY +25.2%) |
| Gross Profit Margin | Rate 30.9% / Year on year against the same period last year +0.2Pt |
| Operating profit margin | Rate 13.3% / Year on year against the same period last year +1.1Pt |
| Selling, general and administrative expenses | ¥5,288 million |
| Results for the three months of the current quarter | Revenue: ¥30,002 million; gross profit: ¥9,269 million; operating profit: ¥3,980 million; ordinary profit: ¥4,142 million; profit attributable to owners of parent for the quarter: ¥2,853 million |
| Full-year earnings forecast | Net Sales ¥117,850 million / Gross profit ¥35,680 million / Operating profit ¥12,900 million / Ordinary income ¥13,350 million / Profit attributable to owners of the parent ¥8,970 million / Annual dividend 66 Yen per share |
| Self-assessment against the plan | Q1 significantly exceeded expectations |
| Segment results | Laboratory Net Sales ¥18,610 million / Year on year against the same period last year +17.3% / Industry Net Sales ¥6,696 million / Year on year against the same period last year +18.5% / Medical Net Sales ¥4,543 million / Year on year against the same period last year +14.2% |
| Breakdown of Factors Affecting the Change | Gross profit Impact of higher sales +¥1.34 billion / Gross margin improvement +¥40 million / Product mix +¥60 million / Price revision +¥80 million / Foreign Exchange -¥100 million |
| Key KPIs | Indicator name Total e-commerce sales / Value ¥11,173 million / Year on year against the same period last year +28.2%, Indicator name Product Range / Value 1,408 10,000 products / Year on year against the same period last year +10.9%, Indicator name Sales of products listed exclusively online / Value ¥6,548 million / Year on year against the same period last year +33.5%, Indicator name Service revenue / Value ¥943 million / Year on year against the same period last year +2.5%, Indicator name Original-product sales / Value ¥10,220 million / Year on year against the same period last year +22.6%, Indicator name Overseas Revenue / Value ¥1,674 million / Year on year against the same period last year +10.1% |
| Number of employees | Headcount increased by 47 from the end of Q1 of the previous fiscal year |
| Assumptions Underlying the Business Outlook | Laboratory and Industry segment revenue growth rate Up 7.5% year on year / Medical segment revenue growth rate 1.0% increase / Full-year gross margin Expected to remain at the previous year's level (30.3%) / Extraordinary loss ¥244 million expected |
| Risk amount incorporated into the outlook | Extraordinary loss of ¥244 million (demolition of the old Rental & Calibration Center building and consolidation of logistics bases in the Kanto area) |
| Annual Dividend | Annual dividend per share Annual dividend per share: ¥66.00 / Interim Not disclosed / End of period Not disclosed |
| Capital expenditures | ¥219 million (increase in property, plant and equipment from the end of the previous fiscal year) |
| New initiatives | Launch of the new AXEL 2.0 search engine, Establishment and planned completion of a new Rental & Calibration Center, Expansion of Smart DC, Updating delivery information and securing alternative products through system integration with suppliers |
Items this document does not state (10)
Progress against full-year forecastUnit price and quantity metricsNumber of stores and locationsMedium-term management plan targetsFinancial targetsPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The reasons cited were increased stockpiling demand arising from supply concerns related to the situation in the Middle East, continued sales supported by ample inventory and secured alternative suppliers, strong performance in the semiconductor sector, growth in e-commerce and original products, measures to address higher procurement costs through price revisions, and control of the increase in selling, general and administrative expenses relative to the increase in revenue.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.